Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A non-randomized, open-label study to investigate the effects of imatinib mesylate on the pharmacokinetics of acetaminophen/paracetamol in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP)
A Non-randomized, Open-label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ability to provide written informed consent prior to participation to the study.
Male or female patients ≥ 18 and ≤ 75 years of age
Patients with CML-CP within 6 months of diagnosis (date of initial diagnosis is the date of first cytogenetic analysis). FISH analysis will not be accepted.
Diagnosis of CML in chronic phase with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations and presence of Bcr-Abl
Documented chronic phase CML as defined by:
< 15% blasts in peripheral blood and bone marrow
< 30% blasts plus promyelocytes in peripheral blood and bone marrow
< 20% basophils in the peripheral blood
≥ 100 x 109/L (≥ 100,000 /mm3) platelets
No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
Adequate end organ function as defined by:
total bilirubin < 1.5 x ULN
SGOT and SGPT < 2.5 x UNL
creatinine < 1.5 x ULN
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before initiation of study drug
Patients in late chronic phase, accelerated phase, or blastic phase are excluded
Patients who have received other investigational agents
Patients who received imatinib for any duration prior to study entry
Patient received any treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide
Patients with another primary malignancy except if the other primary malignancy is neither currently clinically significant or requiring active intervention
Patients who are:
of childbearing potential without a negative pregnancy test prior to baseline
male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial
Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Patient with a severe or uncontrolled medical condition (i.e., uncontrolled diabetes, chronic renal disease)
Patient previously received radiotherapy to ≥ 25% of the bone marrow
Patient had major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery
Patients with an ECOG Performance Status Score ≥ 3
Patients with International normalized ratio (INR) or partial thromboplastin time (PTT) > 1.5 x IULN, with the exception of patients on treatment with oral anticoagulant
Patients with known positivity for human immunodeficiency virus (HIV)
baseline testing for HIV is not required
Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Patients with identified sibling donors where allogeneic bone marrow transplant is elected as first line treatment
Patients who are chronic users of acetaminophen or medications containing acetaminophen.
Patients who received acetaminophen or medications containing acetaminophen within 72 hours prior to study entry.
Other protocol-defined inclusion/exclusion criteria may apply